Letter to Shareholders - January 2019

Letter to Shareholders - January 2019

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Announces Third Quarter 2018 Business Update

Celyad Announces Third Quarter 2018 Business Update

Celyad to Participate at Upcoming Healthcare Conferences

Celyad to Participate at Upcoming Healthcare Conferences

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Generating Allogeneic CAR T cells without Gene Editing

Generating Allogeneic CAR T cells without Gene Editing

Functional screening of different anti-B7H6 CAR designs

Functional screening of different anti-B7H6 CAR designs

Differential effects of target ligands upon NKG2D CAR T cell activation

Differential effects of target ligands upon NKG2D CAR T cell activation

Overcoming target‐driven fratricide for CAR‐T cell therapy

Overcoming target‐driven fratricide for CAR‐T cell therapy